Institutional Repository of Vilnius University
Berberine, a natural inhibitor of pcsk9, as a potential adjuvant in cancer therapy /
Abstract
dc:descriptionBerberine, a bioactive compound mainly extracted from Rhizoma coptidis plant, has historically been used to treat variety of conditions. Nowadays, berberine has attracted attention for its potential as an adjuvant in cancer therapy. It has been reported as an inhibitor of PCSK9, a protein encoded by PCSK9 gene, which is involved in lipid metabolism and is connected to cancer progression. Emerging research finds that PCSK9 is involved into cancer cells immune evasion mechanisms, modulates composition of cellular membrane, and impacts apoptotic and cell proliferation signals in cancer cells. In this study, we selected a panel of tumor cell lines and assed their sensitivity to berberine treatment. MTT and LDH assay revealed that A431 cell line that expresses high levels of PCSK9 is particularly sensitive to berberine. In this cell line, berberine treatment strongly downregulates PCSK9 levels at nucleic acid level and upregulates LDLR levels at protein level. To evaluate the cytotoxic potential of berberine, we tested three chemotherapeutic agents: etoposide, sorafenib and cisplatin. Cytotoxicity of those drugs was assessed alone and in combination with berberine, to confirm the presence of synergistic effects. As a future direction, we aim to further investigate molecular mecha-nisms underlying this synergy to identify most effective combination involving berberine for cancer therapy.
Degree
thesis:*- Grantor dc:publisher
- Institutional Repository of Vilnius University
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Šatrova, Valerija,
Subjects
dc:subject × 1Rights
dc:rights- Statement dc:rights
-
- info:eu-repo/semantics/openAccess
- Language dc:language
- eng
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.vu.lt/VU:ELABAETD239024899&prefLang=en_US